Fresenius SE / Capital Increase 11.08.2008 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius resolves on capital increase The Management Board of Fresenius SE resolved today, with the consent of the Supervisory Board, to issue up to 2,748,057 new ordinary shares and up to 2,748,057 new preference shares from authorized capital without subscription rights. The new shares will be placed with institutional investors by way of an accelerated bookbuilt offering. There will be no public offering. The capital increase is the second component of the long-term financing of the acquisition of APP Pharmaceuticals, Inc. The residual financing requirement will consist of debt instruments. The acquisition of APP Pharmaceuticals is an important step in the growth strategy of Fresenius Kabi, a business segment of Fresenius SE. With this acquisition, Fresenius Kabi enters the U.S. pharmaceuticals market and achieves a leading position in the global I.V. generics market. This North American platform provides further attractive growth opportunities for Fresenius Kabis existing product portfolio. The Else Kröner-Fresenius-Foundation has informed us that, as part of the capital increase, it will purchase approximately 10 % of the new ordinary shares. After issuance of the new shares, the total number of outstanding ordinary shares and preference shares of Fresenius SE will each increase from currently 77,678,718 to up to 80,426,775. The new shares are expected to be included in the quotation of the shares of Fresenius SE in the regulated market at the Frankfurt, Munich and Düsseldorf stock exchanges. They will have full dividend entitlement for the fiscal year 2008. Deutsche Bank and Commerzbank are acting as Joint Lead Managers and Joint Bookrunners and WestLB as Joint Lead Manager for the offering. Capital Increase Data Issuer:Fresenius SE Transaction Structure: Capital increase without subscription rights Offering: Up to 2,748,057 new ordinary shares Up to 2,748,057 new preference shares Placement of Shares: Private placement to German and international institutional investors Stock Exchanges: Regulated Market Frankfurt (Prime Standard), Munich, Düsseldorf Bank Consortium: Joint Bookrunner: Deutsche Bank AG, Commerzbank AG Joint Lead Manager: Deutsche Bank AG, Commerzbank AG, WestLB AG The Management Board Bad Homburg v.d.H., August, 11 2008 End of note DGAP 11.08.2008 --------------------------------------------------------------------------- Language: English Issuer: Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Deutschland Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: ir-fre@fresenius.com Internet: www.fresenius.com ISIN: DE0005785638, DE0005785604 WKN: 578563, 578560 Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf, München; Freiverkehr in Berlin, Hannover, Stuttgart, Hamburg; Terminbörse EUREX End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Fresenius SE: Fresenius resolves on capital increase
| Source: EQS Group AG